Search - tctmd.com

Displaying 61 - 80 of 230

Sort: Relevancy | Date

Presentation TCT 2015

Access Alternatives in Long SFA Disease

Presenter: Hans Krankenberg, Lindsay S. Machan, Andrej Schmidt

October 11, 2015

Presentation TCT 2015

OCT-Guided CTO Crossing and Atherectomy: Are There Advantages of Image-Guided Intervention?

Presenter: Hans Krankenberg, Lindsay S. Machan, Roger Gammon

October 11, 2015

Presentation TCT 2015

Has the TASC Classification Scheme Been Made Obsolete by Todays Antiproliferative Therapeutics?

Presenter: Hans Krankenberg, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

Lithoplasty in Calcified SFA Lesions: Update on Outcomes and Future Trials

Presenter: Prakash Krishnan, Mahmood K. Razavi, Todd J. Brinton

October 11, 2015

Presentation TCT 2015

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

Presenter: Prakash Krishnan, Mahmood K. Razavi, Lawrence A. Garcia

October 11, 2015

Presentation TCT 2015

A Master Class in Atherectomy: Choices, Strategies, and Execution

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Presenter: Prakash Krishnan, Mahmood K. Razavi, Christopher D. Owens

October 11, 2015

Presentation TCT 2015

Update on Bioresorbable Scaffolds for PAD

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Presenter: Julie Logan, George L Adams

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Presenter: Julie Logan, William A. Gray

October 11, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Daily News

在经股 TAVR 后切口部位缝合方面 ProGlide 优于 Prostar XL

September 09, 2015

Advertisement

Access Alternatives in Long SFA Disease

OCT-Guided CTO Crossing and Atherectomy: Are There Advantages of Image-Guided Intervention?

Has the TASC Classification Scheme Been Made Obsolete by Todays Antiproliferative Therapeutics?

Lithoplasty in Calcified SFA Lesions: Update on Outcomes and Future Trials

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

A Master Class in Atherectomy: Choices, Strategies, and Execution

Biomimetic Stents: Rationale and Current Clinical Results

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Update on Bioresorbable Scaffolds for PAD

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

在经股 TAVR 后切口部位缝合方面 ProGlide 优于 Prostar XL

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content